ProQR Therapeutics (PRQR) Accumulated Expenses (2021 - 2022)

ProQR Therapeutics (PRQR) has disclosed Accumulated Expenses for 2 consecutive years, with $8.9 million as the latest value for Q4 2022.

  • Quarterly Accumulated Expenses fell 28.0% to $8.9 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $8.9 million through Dec 2022, down 28.0% year-over-year, with the annual reading at $8.9 million for FY2022, 30.4% down from the prior year.
  • Accumulated Expenses hit $8.9 million in Q4 2022 for ProQR Therapeutics, down from $12.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $12.3 million in Q4 2021 to a low of $8.9 million in Q4 2022.